Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Recruiting
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/22/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +32 locations
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
Recruiting
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Arthritis and Rheumatism Associates ARA Jonesboro, Jonesboro, Arkansas +126 locations
Conditions: Arthritis, Psoriatic
Evaluating a Our Practice Advisory (OPA) to Optimize Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) Test Orders
Recruiting
Our Practice Advisory (OPA) are essential tools in clinical decision-making. The alerts are designed to guide providers towards evidence-based practices and improve patient outcomes. The focus of this initiative is on Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) testing, with the goal of addressing unnecessary repeat testing within a 30-day timeframe, which rarely yields significant new insights. Although randomization occurs at the patient level, the primary outcome of this study... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/22/2025
Locations: UCLA Health System, Los Angeles, California
Conditions: Physician Workflow, Resource Utilization
Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
Recruiting
Background: For children with gigantism, too much growth hormone (GH) in the body causes abnormal growth and many other problems. Current treatments often don t work; no medical treatment is approved by FDA. Researchers want to see if the drug pegvisomant can help. Objective: To test the role of pegvisomant in children and adolescents with gigantism. Eligibility: People ages 2-18 with GH excess for whom usual treatments have not worked or who are not eliginle for them Design: Participants... Read More
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
05/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pituitary Disease
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Recruiting
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Gender:
ALL
Ages:
Between 1 month and 17 years
Trial Updated:
05/22/2025
Locations: New York Medical College, Valhalla, New York +3 locations
Conditions: Solid Tumors, Lymphoma
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Recruiting
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Gender:
ALL
Ages:
60 years and above
Trial Updated:
05/22/2025
Locations: City of Hope, Duarte, California +163 locations
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
Recruiting
The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
05/22/2025
Locations: University of Missouri, Columbia, Missouri
Conditions: Obesity, Vasodilation, Healthy
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
Recruiting
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
05/22/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +14 locations
Conditions: Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Recruiting
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/22/2025
Locations: Banner Desert Medical Center, Mesa, Arizona +833 locations
Conditions: Ischemic Stroke; Ischemic Attack, Transient
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Recruiting
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC characterized on the basis of epidermal growth factor receptor (EGFR) and Programmed-cell death Ligand (PD-L)1 status, in the Phase 2 (expansion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: City of Hope, Duarte, California +43 locations
Conditions: Carcinoma, Non-Small-Cell Lung
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
Recruiting
This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy. Study details include: The... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: University of Alabama at Birmingham- Site Number : 8400026, Birmingham, Alabama +75 locations
Conditions: Lung Transplant Rejection
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
Recruiting
This is a multicenter, randomized, single-blind pivotal study to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels in patients with coronary artery disease. The objective is to establish the safety and efficacy of the Magic TouchTM Drug coated balloon in treatment of small vessels (≤2.75 mm). A total of 1605 subjects will be enrolled in a maximum of 50 study sites located in North America. Additional sites located in Europe and South America... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/22/2025
Locations: Dignity Health - Mercy Gilbert Medical Center, Gilbert, Arizona +25 locations
Conditions: Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases